Last reviewed 2026-04-20 · How we verify

Md-76R (Diatrizoate)

Md-76R (Diatrizoate) is a radiographic contrast agent, a small molecule drug class, originally developed by E.I. du Pont de Nemours and Company. It is currently owned by various generic manufacturers, as it is off-patent. Diatrizoate is used to enhance the visibility of internal structures in medical imaging, particularly in radiography. It was FDA approved in 1954 and has two generic manufacturers. Key safety considerations include its relatively short half-life of 1.8 hours and low bioavailability of 5%.

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Urticaria with erythema
• Hypoxia
• Acute dyspnea
• Tachyarrhythmia
• Anaphylaxis

Key clinical trials

• A Procalcitonin-based Algorithm in Adhesion-related Small Bowel Obstruction (NA)
• Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction
• Optimizing Treatment of Adhesive Small Bowel Obstruction (PHASE3)
• Fluorescence Cholangiography During Cholecystectomy - a RCT (NA)
• Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure (PHASE3)
• Gastrografin for Treating Small Bowel Obstruction in Children (PHASE2,PHASE3)
• The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients. (PHASE4)
• Serum Thyroid Function After Iodinated Contrast Administration

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Md-76R CI brief — competitive landscape report
• Md-76R updates RSS · CI watch RSS
• University of California, San Francisco portfolio CI